Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06440317
Status:
RECRUITING
Last Update Posted:
2024-06-03
First Post:
2024-04-25
Brief Title:
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Investigation of Immunothrombosis in Intensive Care Patients With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PLAQSIRIS
Brief Summary:
Sepsis remains a global scourge Before the SARS-CoV-2 pandemic the World Health Organization estimated approximately 49 million cases annually resulting in 11 million deaths Defined by dysregulated host response to infection sepsis leads to vital organ failure Renal dysfunction affects about half of ICU patients necessitating extracorporeal renal replacement therapy in approximately 10 of cases alongside coagulation system involvement typified by thrombocytopenia Immunothrombotic phenomena are pivotal in sepsis pathophysiology activating coagulation and disrupting immune responses Microcirculatory impairment mediated by neutrophils monocytes and platelets worsens vital organ perfusion Excessive production of Neutrophil Extracellular Traps NETs is implicated in microcirculatory compromise during sepsis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None